1. Academic Validation
  2. E2F activity determines mitosis versus whole-genome duplication in G2-arrested cells

E2F activity determines mitosis versus whole-genome duplication in G2-arrested cells

  • Nat Commun. 2025 Jul 21;16(1):6677. doi: 10.1038/s41467-025-62061-w.
Kibum Kim 1 Jessica Armand 1 2 Sungsoo Kim 1 2 Hee Won Yang 3 4
Affiliations

Affiliations

  • 1 Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.
  • 2 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
  • 3 Department of Pathology and Cell Biology, Columbia University, New York, NY, USA. hy2602@cumc.columbia.edu.
  • 4 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA. hy2602@cumc.columbia.edu.
Abstract

While mitogenic signaling is known to regulate cell-cycle entry during the G1 phase, its function in the G2 phase remains elusive. Here we show that mitogenic signaling controls whether G2-arrested cells proceed through Mitosis or undergo whole-genome duplication. Although mitogenic signaling is not required for the G2/M transition under normal conditions, it modulates E2F transcriptional activity via c-Myc. When G2 arrest occurs due to CDK4/6 and CDK2 suppression, E2F activity levels determine the status of APC/C inactivation and the CDK2-Rb feedback loop. Upon release from G2 arrest, cells maintaining APC/C inactivation promptly induce CDK2 activation and FoxM1 phosphorylation, driving mitotic entry. Conversely, APC/C reactivation degrades cyclin A and abolishes the CDK2-Rb loop, necessitating CDK4/6 activation for cell-cycle re-entry. This regulatory mechanism mirrors the G1-phase process, resulting in whole-genome duplication. In Cancer cells, this process promotes genome instability and oncogene amplification, contributing to aggressive behavior. These findings reveal a previously unrecognized mitogen-dependent checkpoint that governs cell fate in the G2 phase.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15557
    99.40%, ATR Inhibitor